Hindawi Publishing Corporation Science and Technology of Nuclear Installations Volume 2014, Article ID 839369, 3 pages http://dx.doi.org/10.1155/2014/839369



Editorial

Molybdenum-99 (99Mo): Past, Present, and Future

Mushtaq Ahmad, 1 George Vandegrift, 2 and Pablo Cristini 3

- ¹ Isotope Production Division, Pakistan Institute of Nuclear Science and Technology, Nilore, Islamabad 45650, Pakistan
- ² Argonne National Laboratory, 9700 South Cass Avenue, Argonne, IL 60439, USA
- ³ Ezeiza Atomic Center, National Commission of Atomic Energy, Buenos Aires, Argentina

Correspondence should be addressed to Mushtaq Ahmad; amushtaql@hotmail.com

Received 1 December 2013; Accepted 1 December 2013; Published 29 January 2014

Copyright © 2014 Mushtaq Ahmad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Molybdenum-99 (99 Mo, half-life = 66 h) is a parent radionuclide of a diagnostic nuclear isotope. It decays in technetium-99 m (99mTc, half-life = 6 h), which is used in over 30 million procedures per year around the world. To meet worldwide demand for ^{99m}Tc-radiopharmaceuticals, fresh $^{99}\mathrm{Mo/}\,^{99\mathrm{m}}\mathrm{Tc}$ must be delivered regularly to nuclear medical centers, week after week. The risks of global 99 Mo supply disruptions increased significantly since 1995 and have been experienced for different reasons. Since the last quarter of 2007, global Mo-99 supplies have been severely disrupted by recurring operational problems at a handful of aging research reactor (NRU Canada, HFR Netherlands, SAFARI-1 South Africa, BR2 Belgium and OSIRIS France) and processing facilities (MDS Nordion in Canada, Mallinckrodt in the Netherlands, IRE in Belgium, and NTP in South Africa). These few facilities are meeting the bulk of the worldwide demand. With the aging of the 99Mo supply network, it is necessary for world Mo-99 market to consider new reliable supply sources. The present and future shortage of 99m Tc or its parent is a worldwide issue. A research reactor is only one piece of the linear supply chain of 99 Mo/99m Tc that exists today. In April 2010, the United States and 46 other countries signed an agreement to phase out HEU for civilian uses to reduce proliferation concerns. Now scientists and engineers involved in ⁹⁹Mo production are working to determine how to continue to make 99 Mo with (1) low-enriched uranium (LEU, <20% 235 U) or (2) other alternatives that do not require fissioning of 235 U. To overcome the shortage of various routes of its production by accelerators and reactors generating high

and low specific activity $^{99}\mathrm{Mo}$ or $^{99\mathrm{m}}\mathrm{Tc}$ directly is being researched.

Investigators were invited to contribute original research articles as well as review articles to stimulate the continuing efforts to understand the issues related to production of ⁹⁹Mo that is acceptable to end users and environmentalists. The article selected for this special issue represent the rich and many-faceted technical know-how that we have the pleasure of sharing with our readers. We would like to thank the authors for their excellent contributions and patience in assisting us. Finally, the fundamental work of all reviewers on these papers is also highly appreciated.

This special issue contains nine papers, where four papers deal with the production of ⁹⁹Mo using LEU targets in a reactor. Two papers are on ^{99m}Tc generators development and its utilization. One paper deals with the production of ⁹⁹Mo and ^{99m}Tc using a cyclotron. An article on immobilization of higher activity wastes from reactor production of ⁹⁹Mo is also included in this issue. One paper deals with research and development of chemical process, hot-cell infrastructure, and commercial production of ⁹⁹Mo.

In the paper entitled "99mTc Generator Development: Up-to-date" Tc recovery technologies for increasing the effectiveness of 99Mo utilization" by V. S. Le (Australia) presents a review on the 99Mo sources available today and on the 99mTc generators developed up to now for increasing the effectiveness of 99Mo utilization. The latest results of the endeavors in this field are also surveyed in regard to the technical solution for overcoming the shortage of 99Mo

supply. The technical topics are grouped and discussed to reflect the similarity in the technological process of each group. The following topics are included in this review.

- (i) High specific activity ⁹⁹Mo (the issues for current production, efforts for more effectiveutilization, the ^{99m}Tc generator based on high-specific activity ⁹⁹Mo, and ^{99m}Tc concentration units)
- (ii) Low specific activity ⁹⁹Mo (⁹⁹Mo production based on neutron capture and accelerators' direct production of ^{99m}Tc and the methods of increasing the specific activity of ⁹⁹Mo using the Szilard-Chalmersreaction and a high power isotope separator.)

The entitled articles "Immobilisation of higher activity wastes from nuclear reactor production of ⁹⁹Mo" by M. Stewart et al. (Australia) discusses progress in waste-form development and processing to treat ANSTO's intermediate-level waste (ILW) streams arising from ⁹⁹Mo production. The various waste forms and the reason for the process option chosen are reviewed. The options considered were cement-based, glass, glass-ceramic, and ceramic waste forms.

The entitled paper "Evaluation of 99 Mo and 99m Tc productions based on a high-performance cyclotron" by J. Esposito et al. (Italy) describes possibilities to replace the current reactor-based method with the accelerator ones. A feasibility study was started in 2011 based on the new, high-beamcurrent, high-energy cyclotron scheduled to be available in the next coming years at Legnaro Laboratories (LNL). A molybdenum metallic target, enriched to 99.05% 100 Mo, has been assumed, as it is currently available on the isotopes market. A series of in-target quality parameters has thus been calculated for both radionuclides at the End of Bombardment (EOB), based on the maximum (i.e., $500 \mu A$) proton-beam output current. TENDL 2012 theoretical excitation functions, extended up to (p,6n) (p,p5n) and (p,2p4n) levels, were used to get a detailed map of the radionuclides expected. Results point out that accelerator-99 Mo is of limited interest for a possible massive production, mainly because of in-target specific activities, which are a factor of 10^4 lower than reactor $^{99}\mathrm{Mo}.$

The article entitled "History and actual state of non-HEU fission-based Mo-99 production with low-performance research reactors" by S. Dittrich (Germany) discusses that 50 years ago, one of the worldwide first industrial production processes able to produce fission-Mo-99 for medical use had started at ZfK Rossendorf (now HZDR, Germany). On the occasion of this anniversary, it is worth mentioning that this original process (called LITEMOL now) together with its target concept used at that time can be applied still. LITEMOL can be adapted very easily to various research reactors and applied at each site, which maybe still of interest for very small-scale producers. Besides this original process, two further and actually proven processes are suitable as well and recommended for small-scale LEU fission Mo-99 production also.

The article entitled "Influence of the generator in-growth time on the final radiochemical purity and stability of 99m Tc

radiopharmaceuticals" by L. Uccelli et al. (Italy) describes both theoretical investigations and preliminary irradiations tests on ¹⁰⁰Mo-enriched samples. The authors argue that both the ^{99g}Tc/ ^{99m}Tc ratio and the ^{99m}Tc specific activity will be different in accelerator-produced Tc than that milked from generator, and this might affect radiopharmaceutical procedures. The aim of this work was the evaluation of possible impacts of different ^{99g}Tc/ ^{99m}Tc isomeric ratios on the preparation of different Tc-labeled pharmaceutical kits. A set of measurements with ^{99m}Tc, eluted from a standard ⁹⁹Mo/ ^{99m}Tc generator, was performed and results on both radiochemical purity and stability studies (following the standard Quality Control procedures) are reported for a set of widely used pharmaceuticals (i.e., ^{99m}Tc-Sestamibi, ^{99m}Tc-ECD, ^{99m}Tc-MAG₃, ^{99m}Tc-DTPA, ^{99m}Tc-MDP, ^{99m}Tc-HMDP, ^{99m}Tc-nanocolloids, and ^{99m}Tc-DMSA).


The entitled articles, the work of S. G. Govindarajan et al. (USA), "Assembly and irradiation modeling of residual stresses in low-enriched uranium foil-based annular targets for molybdenum-99 production" considers a composite cylindrical structure, with low-enriched uranium (LEU) foil enclosed between two aluminum 6061-T6 cylinders. A recess is cut all around the outer circumference of the inner tube to accommodate the LEU foil of open cross-section. To obtain perfect contact at the interfaces of the foil and the tubes, an internal pressure is applied to the inner tube, thereby plastically and elastically deforming it. The residual stresses resulting from the assembly process are used along with a thermal-stress model to predict the stress margins in the cladding during irradiation. The whole process was simulated as a steady-state 2-dimensional problem using the commercial finite element code Abaqus FEA. The irradiation behavior of the annular target has been presented and the effect of the assembly residual stresses has been discussed.


The article entitled "The fission-based 99 Mo production process ROMOL-99 and its application to PINSTECH Islamabad" by R. Muenze et al. (Germany and Pakistan) presents an innovative process for fission based 99 Mo production developed under Isotope Technologies Dresden (ITD) GmbH (former Hans Wälischmiller GmbH (HWM), Branch Office Dresden), and its functionality has been tested and proved at the Pakistan Institute of Nuclear Science and Technology (PINSTECH), Islamabad. Targets made from uranium-aluminum alloy clad with aluminum were irradiated in the core of Pakistan Research Reactor-1 (PARR-1). More than 50 batches of fission ⁹⁹Mo have been produced that meet the international purity/pharmacopoeia specifications using this ROMOL-99 process. The process is based on alkaline dissolution of the neutron-irradiated targets in the presence of NaNO₃, chemically extracting the ⁹⁹Mo from various fission products and purifying the product by column chromatography.

In the article entitled "A solution-based approach for Mo-99 production: Considerations for nitrate versus sulfate media" A. J. Youker et al. (USA) describe how Argonne National Laboratory is assisting two potential domestic suppliers of Mo-99 by examining the effects of a uranyl-nitrate versus a uranyl-sulfate fuel or target solution compositions on Mo-99 production. Uranyl-nitrate solutions are easier to prepare and do not generate detectable amounts of peroxide upon irradiation, but the effect of a high radiation field (radiolysis of nitrate ion) can lead to a large increase in solution pH, which can lead to the precipitation of fission products and uranyl hydroxides. Uranyl-sulfate solutions are more difficult to prepare, and enough peroxide is generated during irradiation to cause precipitation of uranyl peroxide, but this can be prevented by adding a catalyst to the solution. A titania sorbent can be used to recover Mo-99 from a highly concentrated uranyl nitrate or sulfate solution; however, different approaches must be taken to prevent precipitation of uranium and other fission products during Mo-99 production.

In the article entitled "Production cycle for large scale fission Mo-99 separation by the processing of irradiated LEU uranium silicide fuel element targets," A.-H. A. Sameh (Germany) describes experiments and related high-activity demonstrations that highlight the advantage of uranium silicide fuels as a target material for the production of fission Mo-99. Silicide targets combine features predestinating them as feed materials for a large-scale production of fission nuclides when starting from LEU.


Mushtaq Ahmad George Vandegrift Pablo Cristini


















Submit your manuscripts at http://www.hindawi.com

